SynthesisMayo Clinic proceedings2012
Treatment of nightmares with prazosin: a systematic review.
Synthesis in Mayo Clinic proceedings, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 3 syntheses or guidelines pooled it, 267 citations in OpenAlex.
- Psychological Sleep Interventions for Migraine and Tension-Type Headache: A Systematic Review and Meta-Analysis.Scientific reports · 2019Pooled it
- Treatment of Post-Traumatic Stress Disorders with the Alpha-1 Adrenergic Antagonist Prazosin.Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2017Pooled it
- Comparative meta-analysis of prazosin and imagery rehearsal therapy for nightmare frequency, sleep quality, and posttraumatic stress.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2015Pooled it
- Subtype-resolved norepinephrine imaging with an engineered αCell reports methods · 2026Article
- Glymphatic function restored by α1-noradrenergic antagonism alleviates headache allodynia in mice.bioRxiv : the preprint server for biology · 2026Article
- Mechanisms and Clinical Implications of the Post-traumatic Stress Disorder (PTSD)-Cardiovascular Disease Link.Cureus · 2025Review
- Targeting EphA2: a promising strategy to overcome chemoresistance and drug resistance in cancer.Journal of molecular medicine (Berlin, Germany) · 2024Review
- Case series: Continued remission of PTSD symptoms after discontinuation of prazosin.Frontiers in psychiatry · 2023Article
- The influence of sleep on fear extinction in trauma-related disorders.Neurobiology of stress · 2023Article
- Acute sleep interventions as an avenue for treatment of trauma-associated disorders.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2022Article
- Autonomic Dysreflexia following Spinal Cord Injury.Asian journal of neurosurgery · 2022Review
- Case report: Prazosin augmentation for treating comorbid treatment-resistant depression and chronic post-traumatic stress disorder.Frontiers in psychiatry · 2022Article
- Sex differences in noradrenergic modulation of attention and impulsivity in rats.Psychopharmacology · 2021Article
- Assessment and Treatment of Post-Traumatic Stress Disorder at the End of Life #398.Journal of palliative medicine · 2020Article
- The Neurochemical Effects of Prazosin Treatment on Fear Circuitry in a Rat Traumatic Stress Model.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2020Article
- Ecological Disasters and Mental Health: Causes, Consequences, and Interventions.Frontiers in psychiatry · 2020Review
- Treating psychiatric symptoms and disorders with non-psychotropic medications .Dialogues in clinical neuroscience · 2019Review
- Therapeutic Symptomatic Strategies in the Parasomnias.Current treatment options in neurology · 2018Review
- Sleep Disturbances in Australian Vietnam Veterans With and Without Posttraumatic Stress Disorder.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2018Article
- Use of Prazosin for Pediatric PTSD-Associated Nightmares and Sleep Disturbances: A Retrospective Chart Review.Neurology and therapy · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nightmares, frequently associated with posttraumatic stress disorder and clinically relevant in today's world of violence, are difficult to treat, with few pharmacologic options. We performed a systematic review to evaluate the evidence for the use of prazosin in the treatment of nightmares. A comprehensive search was performed using the databases EMBASE, Ovid MEDLINE, PubMed, Scopus, Web of Science, and Cochrane Database of Systematic Reviews, from their inception to March 9, 2012, using keywords prazosin and nightmares/PTSD or associated terms (see text). Two authors independently reviewed titles and abstracts and selected relevant studies. Descriptive data and outcomes of interest from eligible studies were extracted by 1 author, and checked by 2 others. The risk of bias of randomized controlled trials (RCTs) was assessed independently by 2 reviewers. Articles met criteria for inclusion if prazosin was used to treat nightmares, and outcome measures included nightmares or related symptoms of sleep disorders. Our search yielded 21 studies, consisting of 4 RCTs, 4 open-label studies, 4 retrospective chart reviews, and 9 single case reports. The prazosin dose ranged from 1 to 16 mg/d. Results were mixed for the 4 RCTs: 3 reported significant improvement in the number of nightmares, and 1 found no reduction in the number of nightmares. Reduced nightmare severity with use of prazosin was consistently reported in the open-label trials, retrospective chart reviews, and single case reports.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.